Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Cyclophosphamide treatment experiments in mouse models of breast cancer: 4T1 and E0771

ABSTRACT: Cyclophosphamide treatment experiments in mouse models of breast cancer: 4T1 and E0771

PROVIDER: PRJNA787482 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR17179900_1.fastq.gz	Fastqsanger.gz
	SRR17179900_2.fastq.gz	Fastqsanger.gz
	SRR17179901_1.fastq.gz	Fastqsanger.gz
	SRR17179901_2.fastq.gz	Fastqsanger.gz
	SRR17179902_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 96

Similar Datasets

E0771 cultured mouse mammary tumor cell RNA-seq gene expression profiling: impact of activated cyclophosphamide versus interferon-beta, and the role of interferon signaling in cyclophosphamide responses

Project description:RNA-seq analysis of polyA-selected RNA isolated from cultured E0771 mouse breast cancer cells, with or without treatment with activated cyclophosphamide (4HC, 4-hydroperoxy-cyclophosphamide), interferon-beta, and antibody to the type-I interferon receptor IFNAR1. These RNA samples were part of a study where we investigated the role of type-I interferon signaling in therapeutic responses to cyclophosphamide in mouse models of breast cancer [Vergato et al, Canc Res Communic].

2022-03-17 | GSE190534 | GEO

Cyclophosphamide treatment experiments in mouse models of breast cancer: 4T1 and E0771

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-03-17 | GSE190536 | GEO

4T1 cultured mouse mammary tumor cell RNA-seq gene expression profiling: impact of activated cyclophosphamide versus interferon-beta treatment, and the role of interferon signaling in cyclophosphamide responses

Project description:RNA-seq analysis of polyA-selected RNA isolated from cultured 4T1 mouse breast cancer cells, with or without treatment with activated cyclophosphamide (4HC, 4-hydroperoxy-cyclophosphamide), interferon-beta, and antibody to the type-I interferon receptor IFNAR1. These RNA samples were part of a study where we investigated the role of type-I interferon signaling in therapeutic responses to cyclophosphamide in mouse models of breast cancer [Vergato et al, Canc Res Communic].

2022-03-17 | GSE190533 | GEO

E0771 mouse mammary tumor RNA-seq gene expression profiling: impact of time course of metronomic cyclophosphamide treatment of triple negative breast cancer tumors implanted in female C57/BL6N mice

Project description:RNA-seq analysis of polyA-selected RNA isolated from frozen tumor tissue excised from adult female C57/BL6N mice implanted with E0771 tumors in the mammary fat pad. Mice were treated with cyclophosphamide given on a metronomic schedule (treatment at 130 mg/kg per injection, or PBS (vehicle control)) (lab experiment # TD229). Tumor tissue was collected and used for RNAseq analysis at the following time points: day 1, day 2, day 3, day 6, and day 12, with cyclophosphamide treatments given on day 0, and then again on day 6 in the case of the day 12 time point. These tumor RNA samples were part of a study where we investigated the role of type-I interferon signaling in mouse models of breast cancer [Vergato et al, Canc Res Communic].

2022-03-17 | GSE190532 | GEO

4T1 mouse mammary tumor RNA-seq gene expression profiling: impact of time course of metronomic cyclophosphamide treatment of triple negative breast cancer tumors implanted in female BALB/c mice

Project description:RNA-seq analysis of polyA-selected RNA isolated from frozen tumor tissue excised from adult female BALB/c mice implanted with 4T1 tumors in the mammary fat pad. Mice were treated with cyclophosphamide given on a metronomic schedule (treatment every 6 days at 130 mg/kg, or PBS (vehicle control), for a total of 2, 4 or 7 treatment cycles) (lab experiment # TD227). These tumor RNA samples were part of a study where we investigated the role of type-I interferon signaling in mouse models of breast cancer [Vergato et al, Canc Res Communic].

2022-03-17 | GSE190531 | GEO

Ribosome profiling experiments of LRRK2 mouse models

Project description:Ribosome profiling experiments of LRRK2 mouse models

| PRJNA705181 | ENA

E0771 WXS

Project description:E0771 whole exom sequencing

| PRJEB30681 | ENA

Pleiotrophin drives a pro-metastatic immune niche within the breast tumor microenvironment

Project description:Here, we evaluated the effect of Pleiotrophin (PTN) depletion on tumor microenvironment. For this, we utilized a mouse monoclonal antibody against PTN, 3B10. We tested its therapeutic efficacy in 2 mouse breast cancer models, 4T1 (orthotopic, 4th mammary fat pad) and MMTV-PyMT (genetic model). Tumors from control IgG(C44) treated and 3B10 treated mice were sent for RNA sequencing to evaluate transcriptional changes. Additionally, PTN was knocked down in E0771 and E0771-LG syngeneic breast cancer lines. To evaluate transcriptional changes due to PTN depletion, shCtrl and PTN KD cells from E0771 and E0771-LG were evaluated by RNA sequencing. Overall, our results from these 4 sets of experiments show that depletion or blocking PTN results in inflammation related transcript changes suggesting function of PTN in immune regulation.

2023-02-16 | GSE200431 | GEO

Gene expression profile at single cell level of CD45+ immune cells from E0771-Vector control tumor tissue, E0771 wildtype Malt1 overexpression tumor tissue and E0771 paracaspase-deficient Malt1 overexpression tumor tissue.

Project description:To invesitigate the additional paracaspase-independent tumor-promoting effect exist for Malt1. We thus collected E0771-Vector control tumor tissue, E0771 wildtype Malt1 (Malt1-WT) overexpression tumor tissue and E0771 paracaspase-deficient Malt1 (Malt1-PD) overexpression tumor tissue, and sorted out immune cells for 10× Genomics single cell RNA-sequencing (scRNA-seq).

2024-04-18 | GSE242554 | GEO

RNA-seq of E0771-Vector control, E0771-Malt1-WT and E0771 Malt1-PD after T cell killing

Project description:RNA-seq of E0771-Vector control, E0771-Malt1-WT and E0771 Malt1-PD after T cell killing

| PRJNA1014469 | ENA